Clearmind Medicine announced the publication of a patent by the Korean Intellectual Property Office for its innovative MEAI and N-Acylethanolamines combination therapy targeting cocaine addiction.
Ecopipam demonstrated significant efficacy in Phase 3 D1AMOND study, with only 41.9% of pediatric patients experiencing relapse compared to 68.1% on placebo, marking a potential breakthrough for Tourette syndrome treatment.
SciSparc Ltd. has received renewed approval from the Israeli Medical Cannabis Agency for its clinical trial of SCI-210 in children with autism spectrum disorder (ASD).
SciSparc has enrolled the first patient in its clinical trial for SCI-210, a cannabinoid-based treatment for Autism Spectrum Disorder (ASD) in children.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.